These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25559599)

  • 21. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
    Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
    Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
    Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Notter J; Bregenzer A; Vernazza P; Kahlert CR
    Swiss Med Wkly; 2019 Apr; 149():w20053. PubMed ID: 31017649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
    Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
    Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J
    Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact and cost of laboratory monitoring need review even in resource-rich setting.
    Sayana S; Javanbakht M; Weinstein M; Khanlou H
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e97-8. PubMed ID: 21317583
    [No Abstract]   [Full Text] [Related]  

  • 33. [Experience with nevirapine taken once daily in 93 HIV-infected patients].
    Allavena C; François C; Reliquet V; Perre P; Michau C; Peytavin G; Raffi F
    Pathol Biol (Paris); 1999 May; 47(5):563-5. PubMed ID: 10418041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis.
    Salado-Rasmussen K; Theilgaard ZP; Chiduo MG; Bygbjerg IC; Gerstoft J; Lüneborg-Nielsen M; Lemnge M; Katzenstein TL
    PLoS One; 2015; 10(3):e0121111. PubMed ID: 25812161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
    Manosuthi W; Tantanathip P; Chimsuntorn S; Eampokarap B; Thongyen S; Nilkamhang S; Sungkanuparph S
    Int J Infect Dis; 2010 Nov; 14(11):e1013-7. PubMed ID: 20880733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
    Lee YC; Lin SW; Chen MY; Chang SY; Kuo CH; Sheng WH; Hsieh SM; Sun HY; Chang HY; Wu MR; Liu WC; Wu PY; Yang SP; Zhang JY; Su YC; Luo YZ; Hung CC; Chang SC
    PLoS One; 2015; 10(10):e0140574. PubMed ID: 26465325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.